- Stefano Brillanti, MD
- Professor of Gastroenterology, Director, Hepatology Division, University of Siena, Siena, Italy.
Special Issue Introduction
Hepatocellular carcinoma (HCC) represents the fifth most common cancer in men and the ninth in women, and the second most common cause of cancer-related death worldwide. Different from other malignancies, HCC arises in a chronically diseased organ, generally affected by advanced fibrosis or liver cirrhosis. This implies that management of HCC is strongly influenced by the stage and function of the underlying liver condition, generally contraindicating any possibility of systemic chemotherapy. According to the number and size of HCC nodules, and the stage of liver disease, different potentially curative strategies exist, ranging from liver resection, to thermal tumor ablation, to transarterial chemoembolization and to orthotopic liver transplantation. Despite these multiple therapeutic modalities, HCC recurrence may be observed in over 50% of cases within five years. In the present special issue of Hepatoma Research, international experts will address the most controversial issues regarding recurrence of liver tumor. The first topic will be how to diagnose and stage HCC and select the best treatment in the individual patient. Following topics will address the definition of cure of HCC and the problem of recurrence after loco-regional therapies, liver resection, radio-frequency ablation, transarterial chemoembolization and liver transplantation. Finally, the potential role of targeted systemic therapies and immunotherapies in preventing HCC recurrence will be analyzed.
Submission Deadline31 Oct 2019